Disc Medicine receives FDA Fast Track Designation for DISC-0974

Disc Medicine announced that the United States Food and Drug Administration, FDA, has granted Fast Track Designation to DISC-0974 for the treatment of patients with non-dialysis dependent chronic kidney disease, NDD-CKD, and anemia. “Receiving Fast Track designation highlights the unmet need for the millions of NDD-CKD patients with anemia, as well as the potential of DISC-0974 to address this need,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We believe DISC-0974 could be a transformative therapy for these patients and are excited to share additional results from our ongoing Phase 1b/2 study in NDD-CKD patients with anemia this year.”